Open Access
Med Sci (Paris)
Volume 34, Number 12, Décembre 2018
Page(s) 1029 - 1031
Section Le Magazine
Published online 09 January 2019
  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011 ; 144 : 646–674. [CrossRef] [PubMed] [Google Scholar]
  2. Cordier-Bussat M, Thibert C, Sijobert P, et al. Même l’effet Warburg est oxydable- Coopération métabolique et développement tumoral. Med Sci (Paris) 2018 ; 34 : 701–708. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927 ; 8 : 519–530. [CrossRef] [PubMed] [Google Scholar]
  4. Crabtree HG. Observations on the carbohydrate metabolism of tumours. Biochem J 1929 ; 23 : 536–545. [CrossRef] [PubMed] [Google Scholar]
  5. Mathupala SP. Metabolic targeting of malignant tumors: small-molecule inhibitors of bioenergetic flux. Recent Pat Anticancer Drug Discov 2010 ; 6 : 6–14. [Google Scholar]
  6. Zucman-Rossi J, Benhamouche S, Godard C, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene 2007 ; 26 : 774–780. [Google Scholar]
  7. Senni N, Savall M, Cabrerizo Granados D, et al. Beta-catenin-activated hepatocellular carcinomas are addicted to fatty acids. Gut 2018; gutjnl-2017-315448. doi: 10.1136/gutjnl-2017-315448. [Google Scholar]
  8. Witney TH, Pisaneschi F, Alam IS, et al. Preclinical evaluation of 3–18F-fluoro-2,2-dimethylpropionic acid as an imaging agent for tumor detection. J Nucl Med 2014 ; 55 : 1506–1512. [CrossRef] [PubMed] [Google Scholar]
  9. Holubarsch CJ, Rohrbach M, Karrasch M, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007 ; 113 : 205–212. [CrossRef] [PubMed] [Google Scholar]
  10. Conti R, Mannucci E, Pessotto P, et al. Selective reversible inhibition of liver carnitine palmitoyl-transferase 1 by teglicar reduces gluconeogenesis and improves glucose homeostasis. Diabetes 2011; 60b : 644–51. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.